I1F-MC-RHDC
Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered with Tirzepatide in Adult Participants with Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)
- Sex at Birth: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied: Psoriasis
Study Purpose
The purpose of this research study is to learn more about tirzepatide used with ixekizumab. Tirzepatide is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, or lose weight and keep it off. Tirzepatide is being investigated in this study to see if weight loss improves plaque psoriasis.
Who Can Participate
Age: 18 and older
Locations
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: SITE00002362
- StudyID: 2024-01566
- ClinicalTrials.gov: NCT06588283
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422